Summary
Sangamo Therapeutics, Inc., a clinical-stage biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company offers zinc finger protein (ZFP), a technology platform for making zinc finger nucleases, which are proteins used in modifying DNA sequences by adding or knocking out specific genes; and ZFP transcription factors proteins used in increasing or decreasing gene expression. It develops SB-525, which is in Phase III AFFINE clinical trial for the treatment of hemophilia A; ST-920, a gene therapy, which is in Phase I/II STAAR clinical trials for the treatment of Fabry disease; and SAR445136, a cell therapy, which is in Phase I/II PRECIZN-1 clinical trials for the treatment of sickle cell disease. The company also develops TX200, chimeric antigen receptor for the treatment of HLA-A2 mismatched kidney transplant rejection; KITE-037, a cell therapy for the treatment of cancer; ST-501 for the treatment of tauopathies; and ST-502 for the treatment of synucleinopathies, including Parkinson's disease and neuromuscular disease. It has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Brisbane, California.
History
The company was founded in 1995 in Richmond, California. It was originally known as Sangamo Biosciences, Inc. before changing names in 2017. In September 2018, it had 182 employees. Sandy Macrae is the president. In 2018, Edward Rebar became the senior vice president and chief technology officer of Sangamo.
Mission
Our mission is to transform the lives of people with serious diseases by leveraging our cutting-edge technology platforms of genomic medicine to engineer cells, proteins and tissues.
Vision
Our vision is to be a leading developer of innovative and novel candidate therapeutics, enabling our team to revolutionize the treatment of patients with serious diseases.
Key Team
Dr. R. Andrew Ramelmeier Ph.D. (Exec. VP of Technical Operations)
Dr. Jason D. Fontenot Ph.D. (Sr. VP & Chief Scientific Officer)
Ms. Aron Feingold (Head of Corp. Communications & Investor Relations Officer)
Mr. Scott B. Willoughby (Sr. VP, Gen. Counsel & Corp. Sec.)
Ms. Whitney Jones (Sr. VP & Chief People Officer)
Dr. Nathalie Dubois-Stringfellow Ph.D. (Chief Devel. Officer)
Ms. Heather Erickson (Chief of Staff)
Recognition and Awards
Sangamo was listed in the 2013 FierceBiotech 15 as one of the top 15 companies to watch in the biotechnology industry. Additionally, the company has received numerous honors for its products and research, including the 2006 Tibbetts Award, the 2012 Frost & Sullivan Technology innovation of the Year Award, and the 2013 Smithsonian National Design Award.
References
United States 